These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21126843)

  • 41. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.
    Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ
    Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
    Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
    J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Controlled release of paclitaxel using a drug-eluting stent through modulation of the size of drug particles in vivo.
    Jang BN; Kang SN; Eom TG; Han DK; An SH; Noh I; Kum CH
    J Biomed Mater Res B Appl Biomater; 2018 Aug; 106(6):2275-2283. PubMed ID: 29087014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease.
    Zhang F; Dong L; Qian J; Ge J
    Ann Med; 2011 Feb; 43(1):75-9. PubMed ID: 21171912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro and in vivo performance of a dual drug-eluting stent (DDES).
    Huang Y; Venkatraman SS; Boey FY; Lahti EM; Umashankar PR; Mohanty M; Arumugam S; Khanolkar L; Vaishnav S
    Biomaterials; 2010 May; 31(15):4382-91. PubMed ID: 20189244
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Choosing a drug-eluting stent: a comparison between CYPHER and TAXUS.
    Perin EC
    Rev Cardiovasc Med; 2005; 6 Suppl 1():S13-21. PubMed ID: 15665793
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlled release of paclitaxel from heparinized metal stent fabricated by layer-by-layer assembly of polylysine and hyaluronic acid-g-poly(lactic-co-glycolic acid) micelles encapsulating paclitaxel.
    Kim TG; Lee H; Jang Y; Park TG
    Biomacromolecules; 2009 Jun; 10(6):1532-9. PubMed ID: 19361215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sirolimus coating on heparinized stents prevents restenosis and thrombosis.
    Bae IH; Lim KS; Park DS; Shim JW; Lee SY; Jang EJ; Park JK; Kim JH; Jeong MH
    J Biomater Appl; 2017 May; 31(10):1337-1345. PubMed ID: 28436251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
    Bhargava B; Reddy NK; Karthikeyan G; Raju R; Mishra S; Singh S; Waksman R; Virmani R; Somaraju B
    Catheter Cardiovasc Interv; 2006 May; 67(5):698-702. PubMed ID: 16575925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of interfacial layer wettability and thickness on the coating morphology and sirolimus release for drug-eluting stent.
    Bedair TM; Yu SJ; Im SG; Park BJ; Joung YK; Han DK
    J Colloid Interface Sci; 2015 Dec; 460():189-99. PubMed ID: 26319336
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vitamin-C delivery from CoCr alloy surfaces using polymer-free and polymer-based platforms for cardiovascular stent applications.
    Thiruppathi E; Mani G
    Langmuir; 2014 Jun; 30(21):6237-49. PubMed ID: 24832897
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro.
    Kraitzer A; Kloog Y; Haklai R; Zilberman M
    J Pharm Sci; 2011 Jan; 100(1):133-49. PubMed ID: 20623695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Microsphere-integrated drug-eluting stents: PLGA microsphere integration in hydrogel coating for local and prolonged delivery of hydrophilic antirestenosis agents.
    Indolfi L; Causa F; Giovino C; Ungaro F; Quaglia F; Netti PA
    J Biomed Mater Res A; 2011 May; 97(2):201-11. PubMed ID: 21394898
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.